Thanks for the explanation. Yes, GLENMARK’s investment in ICHNOS as a percentage of its profit after tax is quite substantial. Your remark indicate that if clinical trials are successful, the molecules/therapies being developed by ICHNOS could be very effective. The other question of course is to the safety of these molecules and how likely is such an innovative drug to successfully pass through the clinical trials…
Disclosure: invested, ~2% of portfolio.
| Subscribe To Our Free Newsletter |
